Table 3. Multivariate analysis between SUA and 90-day functional outcome.
| SUA (μmol/L) |
mRS 2–6, n (%) |
Unadjusted model | Model 1 | Model 2 | Model 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value | aOR (95% CI) | P value | |||||
| Quartile 1 | 150 (76.92) | Reference | Reference | Reference | Reference | |||||||
| Quartile 2 | 133 (68.21) | 0.644 (0.411–1.009) | 0.055 | 0.621 (0.382–1.008) | 0.054 | 0.675 (0.311–1.462) | 0.319 | 0.624 (0.285–1.365) | 0.238 | |||
| Quartile 3 | 137 (70.26) | 0.709 (0.451–1.115) | 0.136 | 0.754 (0.461–1.233) | 0.260 | 1.000 (0.449–2.231) | 0.999 | 0.905 (0.405–2.021) | 0.807 | |||
| Quartile 4 | 130 (66.67) | 0.600 (0.384–0.938) | 0.025 | 0.567 (0.345–0.933) | 0.026 | 0.364 (0.154–0.858) | 0.021 | 0.367 (0.154–0.876) | 0.024 | |||
Quartile 1: <245.85; Quartile 2: 245.85–297.45; Quartile 3: 297.45–364.95; Quartile 4: ≥364.95. Model 1, adjusted for age, male, atrial fibrillation, diabetes mellitus, baseline NIHSS, prior stroke, smoker, using alcohol, onset to recanalization, location of occlusion, and stroke subtype. Model 2, Model 1 + diuretics before stroke onset, triglyceride level, blood urea nitrogen, and eGFR (significant variables from Table 2). Model 3, Model 2 + intravenous r-tPA, mTICI 2b/3, and WBC (significant variables from Table S3). SUA, serum uric acid; mRS, modified Rankin Scale; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; NIHSS, National Institute of Health stroke scale; eGFR, estimated glomerular filtration rate; r-tPA, recombinant human tissue-type plasminogen activator; mTICI, modified thrombolysis in cerebral infarction score; WBC, white blood cell.